- Home
- PHLT vs CTKB Comparison
PHLT vs CTKB Comparison
Compare PHLT & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHLT
- CTKB
- Stock Information
- Founded
- PHLT 1976
- CTKB 1990
- Country
- PHLT United States
- CTKB United States
- Employees
- PHLT N/A
- CTKB N/A
- Industry
- PHLT Other Consumer Services
- CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PHLT Consumer Discretionary
- CTKB Health Care
- Exchange
- PHLT Nasdaq
- CTKB Nasdaq
- Market Cap
- PHLT 601.2M
- CTKB 526.7M
- IPO Year
- PHLT N/A
- CTKB 2021
- Fundamental
- Price
- PHLT $7.69
- CTKB $3.96
- Analyst Decision
- PHLT Buy
- CTKB Hold
- Analyst Count
- PHLT 2
- CTKB 4
- Target Price
- PHLT $7.88
- CTKB $6.00
- AVG Volume (30 Days)
- PHLT 1.2M
- CTKB 920.6K
- Earning Date
- PHLT 11-05-2025
- CTKB 11-04-2025
- Dividend Yield
- PHLT N/A
- CTKB N/A
- EPS Growth
- PHLT N/A
- CTKB N/A
- EPS
- PHLT N/A
- CTKB N/A
- Revenue
- PHLT $137,357,000.00
- CTKB $196,035,000.00
- Revenue This Year
- PHLT $12.38
- CTKB $0.09
- Revenue Next Year
- PHLT $10.09
- CTKB $7.45
- P/E Ratio
- PHLT N/A
- CTKB N/A
- Revenue Growth
- PHLT 15.21
- CTKB N/A
- 52 Week Low
- PHLT $2.17
- CTKB $2.37
- 52 Week High
- PHLT $7.74
- CTKB $7.63
- Technical
- Relative Strength Index (RSI)
- PHLT 81.89
- CTKB 50.36
- Support Level
- PHLT $7.56
- CTKB $3.72
- Resistance Level
- PHLT $7.67
- CTKB $4.14
- Average True Range (ATR)
- PHLT 0.03
- CTKB 0.20
- MACD
- PHLT -0.11
- CTKB -0.03
- Stochastic Oscillator
- PHLT 91.67
- CTKB 47.06
About PHLT Performant Healthcare Inc. Common Stock
Performant Healthcare Inc provides solutions to payers in the healthcare industry to identify, prevent, and recover waste and improper payments by leveraging technology, analytics, and proprietary data assets.
About CTKB Cytek Biosciences Inc.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.